Table 2 SBRT reirradiation for lung cancer
From: Stereotactic body radiation therapy in the re-irradiation situation – a review
Clinical trial | Poltinnikov et al. | Coon et al. | Kelly et al. |
|---|---|---|---|
No. patients/treatment | 17/17 | 12/12 | 36/36 |
Dose 1 st RT course | ≥ 50 Gy | n/s | median 61.5 Gy |
(range, 30–79.2 Gy) | |||
Interval (median) | n/s | n/s | 22.0 months (range, 0–92 months) |
Total re-irradiation dose | median 32Gy (17.5 – 42.0) | 60Gy | 50 Gy (72%) |
40 Gy (17%) | |||
Other (11%) | |||
Single fraction dose | median 4Gy (2.5 – 4.2) | 20Gy | 12.5 Gy (72%) |
10Gy (17%) | |||
Other (11%) | |||
Technology | SBF | Cyberknife | SBF, 4D-CT, FDG-PET |
Target size | median field size 95cm2 (30–189) | median GTV 14.3cc | Tumor size (median) 1.7cm |
(range, 0.6–3.8 cm) | |||
Symptom relief | 11/13 | n/s | n/s |
Median follow-up (range) | n/s | 12 months | 15 months (4–45) |
Local control | 5/17 responders | 92% @ 1a | 92% |
Median Overall survival (range) | 5.5 months (2.5–30) | 67% @ 1a | 59% @ 2a |
Toxicity | G2 esophagitis n=4 | No G3 toxicity | At least one G3 in 33% of patients |
G2 pneumonits n=1 | |||
G3 peunomitis n=7 | |||
G3 esophagitis n=3 | |||
G3 Skin ulcer n=2 | |||
G3 Cough n=1 | |||
No G4/5 toxicities | |||